An interventional study of Group I (extended platelet-rich fibrin) and Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin) in Furcation Defects, sponsored by Merna Nasser Mohamed Mostafa Ibrahim Elnahas. Completed at 1 site in Egypt. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Merna Nasser Mohamed Mostafa Ibrahim Elnahas · Not applicable, Interventional, and Treatment
The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.
A total of 30 grade II furcation defects will be randomly divided into three groups as follows:
Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.
Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).
Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
42 studies on the registry are indexed under Furcation Defects; 13 are open to participants now.
This study's enrollment of 30 is above the median of 27 across 38 interventional studies indexed under Furcation Defects.
Browse Furcation Defects studies →This is the only study on the registry with Merna Nasser Mohamed Mostafa Ibrahim Elnahas as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.
Procedure: Group I (extended platelet-rich fibrin)
10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).
Procedure: Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)
10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
Procedure: Group III (bioactive glass nanoparticles and covered by a collagen membrane)
mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
bioactive glass nanoparticles and covered by a collagen membrane
The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters
Time frame: 6 months follow up
the secondary outcomes include improvements (decrease)of probing depth in millimetres
Using UNC-15 periodontal probe to measure the probing depth from the base of the pocket to the free gingival margin. All measurements will be rounded off to the nearest millimetre.
Time frame: 3 and 6 months follow up
the secondary outcomes include improvements (decrease)of clinical attachment level loss in millimetres
using a UNC-15 periodontal probe to measure clinical attachment level loss from the cemento-enamel junction (CEJ) to the pocket depth. All measurements will be rounded off to the nearest millimetre
Time frame: 3 and 6 months follow up
the secondary outcomes include improvements (decrease) of gingival recession measured in millimetres
Using a UNC-15 periodontal probe to measure gingival recession from cemento-enamel junction (CEJ) to the free gingival margin. All measurements will be rounded off to the nearest millimetre
Time frame: 3 and 6 months follow up
the secondary outcomes include improvements (decrease) of gingival bleeding index
It's performed through gentle probing of the orifice of the gingival crevice using a UNC-15 periodontal probe. If bleeding occurs within 10 seconds a positive finding is recorded, and the number of positive sites is recorded and then expressed as a percentage of the number of the sites examined.
Time frame: 3 and 6 months follow up
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.